Maze Therapeutics (MAZE) Misses Q4 EPS by 65c

Maze Therapeutics (NASDAQ: MAZE) reported Q4 EPS of ($0.65).

For earnings history and earnings-related data on Maze Therapeutics (MAZE) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Freedom Broker Downgrades Flexsteel (FLXS) to Hold
• Rocket Lab wins $12M in Space Force contracts for satellite network